focus -WSS

focus

author：Wikipedia 2025-10-02 18:05:37 - browse：669

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

entertainment

WSS

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Abridge raises $150m as clinical notes automation market heats up

In 'major milestone,' FDA approves first cell therapy for solid tumors

6 phony surgeries that take placebo to the extreme

As AI regulations shape up, health tech startups beg for clarity

Antivenom research: Lessons from HIV applied in search for universal antidote

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

What does generative AI mean for health care? We asked experts

The Harvard botanist who searched for psychedelics in the Amazon

Tori Bowie and the unacceptable rates of Black maternal death

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In 'major milestone,' FDA approves first cell therapy for solid tumors

Jerome Adams on the need for new antivirals for Covid

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Affirmative action in medical school literally saved lives

New study raises questions about niacin and heart health

focus

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

The Harvard botanist who searched for psychedelics in the Amazon

Medicare inequities exacerbate Puerto Rico’s health disparities

Abridge raises $150m as clinical notes automation market heats up

He's a Nobel laureate. Critics say he was misleading on Covid

Ukraine seeks to reclaim its role as a hub for clinical trials

entertainment

entertainment

knowledge

hotspot